MedPath

Additional effects of moderate-dose fluticasone and salmeterol combination therapy on exacerbations and airflow limitations in patients with COPD in Japa

Not Applicable
Conditions
COPD
Registration Number
JPRN-UMIN000003403
Lead Sponsor
Kyusyu Asthma & COPD Forum
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
1008
Inclusion Criteria

Not provided

Exclusion Criteria

1. other respiratory diseases 2. regular use of inhaled corticosteroids 3. regular use of inhaled and transdermal beta2 agonists 4. severe other orgen diseases 5. active malignancies

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Prevent the numbers and severity of exacerbation/yr/patient
Secondary Outcome Measures
NameTimeMethod
Prevent the decline of FEV1
© Copyright 2025. All Rights Reserved by MedPath